TG Therapeutics Inc (NASDAQ:TGTX)’s traded shares stood at 1.76 million during the last session, with the company’s beta value hitting 2.22. At the close of trading, the stock’s price was $33.88, to imply an increase of 1.47% or $0.49 in intraday trading. The TGTX share’s 52-week high remains $36.84, putting it -8.74% down since that peak but still an impressive 62.1% since price per share fell to its 52-week low of $12.84. The company has a valuation of $5.27B, with an average of 2.62 million shares in intraday trading volume over the past 10 days and average of 3.71 million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for TG Therapeutics Inc (TGTX), translating to a mean rating of 1.50. Of 6 analyst(s) looking at the stock, 0 analyst(s) give TGTX a Sell rating. 0 of those analysts rate the stock as Overweight while 1 advise Hold as 5 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at 0.09.
TG Therapeutics Inc (NASDAQ:TGTX) trade information
After registering a 1.47% upside in the last session, TG Therapeutics Inc (TGTX) has traded red over the past five days. The 5-day price performance for the stock is -1.11%, and 39.08% over 30 days. With these gigs, the year-to-date price performance is 98.36%. Short interest in TG Therapeutics Inc (NASDAQ:TGTX) saw shorts transact 28.33 million shares and set a 7.32 days time to cover.
The extremes give us $20 and $55 for target low and target high price respectively. As such, TGTX has been trading -62.34% off suggested target high and 40.97% from its likely low.
TG Therapeutics Inc (TGTX) estimates and forecasts
Looking at statistics comparing TG Therapeutics Inc share performance against respective industry, we note that the company has outperformed competitors. TG Therapeutics Inc (TGTX) shares are 104.96% up over the last 6 months, with its year-to-date growth rate higher than industry average at 88.89% against 17.30%. The rating firms project that company’s revenue will grow 40.84% compared to the previous financial year.
Revenue forecast for the current quarter as set by 8 analysts is 98.42M. Meanwhile, for the current quarter, a total of 4 analyst(s) estimate revenue growth to 110.84M.Earnings reports from the last fiscal year show that sales brought in 43.97M and 63.47M respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to rise 123.84% before jumping 74.62% in the following quarter.
TGTX Dividends
TG Therapeutics Inc has its next earnings report out in January. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
TG Therapeutics Inc (NASDAQ:TGTX)’s Major holders
TG Therapeutics Inc insiders hold 9.50% of total outstanding shares, with institutional holders owning 66.38% of the shares at 73.35% float percentage. In total, 66.38% institutions holds shares in the company, led by VANGUARD GROUP INC. As of 2024-06-30, the company held over 13.69 million shares (or 9.3645% of shares), all amounting to roughly $243.58 million.
The next major institution holding the largest number of shares is BLACKROCK INC. with 11.39 million shares, or about 7.7891% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $202.6 million.
